new Delhi. Amidst the coronavirus epidemic, everyone is looking forward to the availability of its effective vaccine (Coronavirus vaccine) as soon as possible. Vaccine manufacturers are involved in clinical trials. In addition to the safety concerns of the vaccine under trial, the haggling of its deals has become a new concern as rich countries have the advantage of pre-booking these vaccines, which may make it unavailable to other countries.
Hong Kong Nasal Spray Vaccine trial
Hong Kong will begin testing for an experimental vaccine that will be given via nasal spray. It will be a dual vaccine – to be used for both influenza and COVID-19. The government of Norway and Hong Kong have funded for this experimental spray. The research being done to deal with the corona epidemic will involve dozens of clinical trials around the world.
According to the Department of Microbiology of the University of Hong Kong, the vaccine is similar to a nasal sprayed flu vaccine already available in the market. This vaccine is designed to destroy the virus that attacks the respiratory system through the nose.
EU’s new deal with Johnson & Johnson
The European Commission has signed a deal with Johnson & Johnson to supply its potential COVID-19 vaccine to 400 million people. This is the third contract for advance purchase signed by the EU. The other two included agreements with AstraZeneca and Sanofi.
According to the World Health Organization, 76 million people of the world are corona infected, the situation will worsen in the coming times
Oxford vaccine still safe in India
At the Postgraduate Institute of Medical Education and Research (PGIMER), about 53 individuals participating in the COVID-19 vaccine trial did not see any major side effects until seven days after vaccination.
COVAX connected China
China has formally joined COVAX as part of the World Health Organization initiative. Kovacs will ensure equal distribution of vaccines in the world. However, the United States and Russia have not yet joined this global vaccine pool.
Moderna will not enforce patent rights
Vaccine manufacturer Moderna has stated that it will not apply patents against other vaccine manufacturers during the epidemic. According to a statement issued by the company, “Moderna recognizes that intellectual property rights play an important role in encouraging investment in research. Other than Moderna’s vaccines, COVID-19 vaccines are under development that could use Moderna’s patented technologies Are. We feel a special obligation under this circumstance to use our resources to end this epidemic as quickly as possible. ”
“When the pandemic continues, Moderna will not apply our COVID-19 related patents that benefit vaccine-makers to combat the pandemic. In addition, any alleged intellectuals for vaccine development during the pandemic period To eliminate property barriers, we are also prepared to license our intellectual property to COVID-19 vaccines to others for the duration of the epidemic.